CTOs on the Move

Ziwi USA

www.ziwipets.com

 
Welcome to ZiwiPeak - Home of healthy, 100% natural dog and cat food. for a complete balanced, healthy and totally natural diet for your pet.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.ziwipets.com
  • 10985 Cody Street Suite 110
    Overland Park, KS USA 66210
  • Phone: 913.291.0189

Executives

Name Title Contact Details

Similar Companies

Organ Recovery Systems

Organ Recovery Systems is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iberia Medical Center

Iberia Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Iberia Medical Center is based in New Iberia, LA. You can find more information on Iberia Medical Center at www.iberiamedicalcenter.com

MetaWorks

MetaWorks is a Medford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 180 locations in 31 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic